Contrast-enhanced [18 F] fluorodeoxyglucose-positron emission tomography/computed tomography in clinical oncology: tumor-, site-, and question-based comparison with standard positron emission tomography/computed tomography

Table 1 Patient characteristics

	Whole patient group	Histopathological confirmation
	(n = 202)	(n = 73)
Age (years)	61.9 ± 14.9	54.2 ± 17.3
Gender (M/F)	120/82	43/30
Tumor type ^a,b
Lung cancer	38	30
Head and neck cancer	22	14
Gastrointestinal cancer^c	31	7
Breast cancer	21	4
Lymphoma	36	9
Melanoma	19	2
Multiple melanoma	15	5
Other^d	18	2
Clinical question ^b
Diagnosis	22	10
Staging	20	11
Restaging^e	33	18
Response to chemotherapy	58	6
Response to radiotherapy	18	6
Post-surgery evaluation	11	0
Surveillance	40	22

Values are mean ± standard deviation.
^aTwo patients were not affected by any oncologic disease after histologic confirmation.
^bTumor type and clinical questions correspond to the groups submitted to the tumor-based and question-based analyses.
^cIncluding esophageal, gastric, and colorectal cancer.
^dGynecologic malignancy (n = 8), testicular cancer (n = 2), sarcoma (n = 3), low-differentiated neuroendocrine carcinoma (n = 4), thymoma (n = 1).
^eSuspected relapse or patients with potentially resectable metastatic disease.

ISSN: 1470-7330